Cardiac NO-activated pathways are discussed to involve cross-talk between cGMP and cAMP signalling [1,2]. Here we have investigated the signalling pathways relating to NO-donor S-nitroso-N-acetylpenicillamine (SNAP) modulation of L-type Ca 2+ current (I Ca,L ) in human right atrial cardiomyocytes. Rozmaritsa et al. BMC Pharmacology 2011, 11(Suppl 1):P55
Material and methods
Experiments were performed on human biopsy tissue from 62 patients in sinus rhythm. I Ca,L was measured with whole-cell voltage-clamp technique.
Results
Application of SNAP (100µM) increased basal I Ca,L from 5.93±0.23 pA/pF to 9.10±0.45pA/pF (p<0.001, n/N=117/ 62). The effect was abolished by inhibition of soluble guanylate cyclase (sGC) with ODQ (30µM), suggesting involvement of cGMP. Stimulator of sGC (BAY 41-2272, 10nM-10µM) also increased I Ca,L and this effect was potentiated in the presence of SNAP. Direct activation of protein kinase G (PKG) with 8-Br-cGMP (100 µM, intracellular application) increased basal I Ca,L . However, not only cGMP but also cAMP was involved, because, the effect of SNAP on I Ca,L was prevented with the protein kinase A blocker (Rp-8-Br-cAMP 1 mM, intracellular). Thus, cGMP may activate I Ca,L via direct activation of PKG and indirect activation of PKA at the same time. It is known, that cAMP-mediated activation of PKA is regulated by cGMP via modulation of phosphodiesterases (PDEs). The selective PDE2 inhibitor EHNA (10µM) did not affect basal or SNAP-stimulated I Ca,L , therefore PDE2 does not regulate basal cAMP level. In contrast, PDE3 inhibition with cilostamide (1µM) increased basal I Ca,L , suggesting that PDE3 is involved in basal cAMP level regulation. Interestingly, the cilostamide-induced increase in I Ca,L is blunted upon addition of SNAP, most probably via activation of PDE2 by SNAP-mediated cGMP increase (Figure 1) . Similarly, SNAP blunted enhancement of I Ca,L by PKA activation with isoprenalin (1µM; 18.07 ± 1.12 pA/pF vs 23.06 ± 1.36 pA/pF, p<0.001, n/N=21-39/18), however, this effect was prevented by PDE2 inhibition with EHNA. 
